Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen To Report First Quarter 2020 Financial Results

SAN FRANCISCO, April 24, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a...
April 20, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen Reports UK Court Ruling

SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using...
March 02, 2020 16:01 ET | Source: FibroGen, Inc

FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
February 18, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results

SAN FRANCISCO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020....
February 11, 2020 17:00 ET | Source: FibroGen, Inc

FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease

SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the U.S. Food and Drug Administration (FDA) has completed its filing review of its New Drug...
February 11, 2020 08:00 ET | Source: FibroGen, Inc

FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference

SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the 9th Annual SVB Leerink Global Healthcare Conference on February 25, 2020. Enrique Conterno,...
January 06, 2020 07:00 ET | Source: FibroGen, Inc

FibroGen Names Enrique Conterno as Chief Executive Officer

SAN FRANCISCO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that its Board of Directors unanimously appointed Enrique Conterno as the company’s Chief Executive Officer...
December 23, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease

SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
December 02, 2019 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List

SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
November 11, 2019 16:01 ET | Source: FibroGen, Inc

FibroGen Reports Third Quarter 2019 Financial Results

Roxadustat Positive Pooled Phase 3 Efficacy and Cardiovascular Safety Data Presented Last Friday at American Society of Nephrology 2019 Kidney WeekPlan to Submit Roxadustat U.S. NDA This Quarter ...